NCT04599140 2026-01-22
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
Clinical Trials
3 trialsNCT04017650 2025-11-20
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT02948348 2021-09-16
Study to Nivolumab Following Preoperative Chemoradiotherapy
National Cancer Center Hospital East
Phase 1/2 Unknown